Using targeted radiation to boost cancer immunotherapy effectiveness
Targeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy response
This study is exploring a new way to make immunotherapy work better for people with advanced cancer by pairing it with a special type of radiation treatment, hoping to help the immune system recognize and fight the cancer more effectively, especially for those who haven't had success with standard treatments.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10994064 on NIH RePORTER |
What this research studies
This research investigates a new approach to enhance the effectiveness of immunotherapy for metastatic cancers by combining it with targeted radionuclide therapy. The goal is to stimulate the body's immune response to recognize and attack tumor cells more effectively, especially in cases where traditional immunotherapy has not been successful. By delivering radiation directly to tumors, the treatment aims to increase immune cell infiltration and activity, potentially leading to better outcomes for patients. This combined therapy could help prevent cancer recurrence and promote long-term survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic cancers, particularly those with immunologically 'cold' tumors that have not responded well to existing immunotherapies.
Not a fit: Patients with localized tumors or those who have already responded well to standard immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with metastatic cancers that currently have limited options.
How similar studies have performed: While combining radiation with immunotherapy is a growing area of interest, this specific approach using targeted radionuclide therapy is relatively novel and has not been extensively tested.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Kerr, Caroline Paula Anne — University of Wisconsin-Madison
- Study coordinator: Kerr, Caroline Paula Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.